Equity Research: Novo Nordisk A/S (NVO)

Recent News & Earnings

Business Summary

I think of Novo Nordisk as one of the most focused large-cap pharmaceutical companies I follow. Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo operates in more than 185 countries and employs approximately 63,000 people. The company's entire identity is built around two disease areas: metabolic diseases (principally diabetes and obesity) and rare diseases. That focus has created extraordinary depth in the GLP-1 space, and it is the reason the company became the most valuable company in Europe at its 2024 peak, before the current drawdown.

Diabetes & Obesity Care (95%+ of Revenue)

This segment is Novo's entire investment case. Ozempic (injectable semaglutide for type 2 diabetes), Wegovy (higher-dose injectable semaglutide for obesity), and Rybelsus (oral semaglutide for type 2 diabetes) are the three pillars. I estimate this segment contributes approximately 95% of total revenue and essentially all revenue growth. The segment grew over 30% in 2023 and 2024 before the deceleration I am now modeling for 2026. Victoza (older liraglutide GLP-1) is declining and increasingly irrelevant.

Rare Disease

I consider this segment strategically important but financially secondary. It includes haemophilia products (NovoSeven, NovoEight, Alhemo), rare blood disorders, and growth hormone products (Norditropin, Sogroya). The rare disease franchise contributes roughly 5% of revenue and has been growing modestly. It provides some diversification from the GLP-1 competitive narrative, but it is not large enough to move the needle on valuation.

GLP-1 Obesity & Diabetes Franchise

I spend most of my analysis time on this segment because it is effectively the entire company. Novo's GLP-1 franchise, anchored by semaglutide, has been the defining pharmaceutical story of the past five years. But 2026 is the year where competitive and regulatory dynamics are catching up, and I want to be precise about what I am watching.

Unit Economics & Margin Profile

I find the gross margin profile of this franchise exceptional. In FY2024, Novo delivered an 85.0% gross margin, among the highest in large-cap pharma, reflecting the combination of premium pricing, patent protection, and manufacturing scale. In FY2025, gross margin compressed to 82.4%, which I attribute to the initial pricing concessions under the 340B program and the early effects of rebate structures. I expect further compression in 2026 as pricing reform bites harder, and I am modeling gross margins in the 79-81% range for the year.

Why This Segment Is the Entire Investment Thesis

The rare disease and endocrine businesses are stable but small. Everything that matters, whether it is revenue growth, margin expansion, competitive positioning, or pipeline value, runs through the GLP-1 franchise. This means when the franchise faces headwinds (as it does now from LLY, compounders, and pricing), the entire investment case is under pressure. I think that is exactly the right framing for where NVO sits today: the franchise is not broken, but it is being repriced by the market.

Industry Context

I think the GLP-1 market is one of the most important structural growth stories in healthcare over the next decade, and that view has not changed despite Novo's recent setbacks. The global GLP-1 market was approximately $70 billion in 2025, and I believe it will reach $122 billion by 2030 and potentially $200 billion by 2033, driven by the growing recognition that obesity is a chronic disease requiring pharmacological treatment. Approximately 1 billion adults globally are obese, and penetration of GLP-1 therapies remains under 5% of the eligible population. That is an enormous addressable market, and I think it is the reason both Novo and Lilly are committing billions in annual capital expenditure to manufacturing capacity.

What I am watching carefully is the competitive structure of this market. For most of the past four years, NVO and LLY had a comfortable duopoly controlling 95% or more of global GLP-1 prescriptions. That structure is shifting. Lilly's tirzepatide (Mounjaro for diabetes, Zepbound for obesity) has demonstrated superior efficacy in head-to-head data, and I believe the market is repricing the relative competitive positions accordingly. Novo held roughly 80% of international GLP-1 market share in 2024. By Q3 2025, Novo's US share had declined to approximately 43% while Lilly's had risen to 57%. This is the core competitive risk I am managing in my analysis, and the CagriSema trial failure has amplified it.

The disruption threats I am tracking alongside direct competition include compounding pharmacies (which have been selling unauthorized semaglutide copies at a fraction of the price), the impact of US drug pricing reform through Most Favoured Nation executive orders, and reduced Medicaid coverage for obesity medications. Each of these individually is manageable; together in 2026, they explain the unprecedented guidance reset I discussed in Section 02.

Competitive Advantages & Moat

1. Semaglutide Intellectual Property

I believe the core patent protection on semaglutide running through approximately 2031 to 2035 (varying by market and formulation) remains the most important moat in Novo's arsenal. This IP gives the company a meaningful runway even in a scenario where competitive intensity increases further. I am watching patent challenge timelines and any developments on biosimilar semaglutide closely, as an accelerated patent cliff would be a material negative to my base case.

2. Manufacturing Scale and CapEx Leadership

Novo has been investing over $6 billion annually in manufacturing capacity, which I think creates a durable operational moat. GLP-1 biologics are extraordinarily difficult to manufacture at scale, and Novo's decade-plus head start in production expertise and plant capacity is not easily replicated. This is one reason I do not expect a meaningful third competitor to emerge in the next 3 years, even as smaller players attempt to enter the space.

3. Brand Equity and Physician Relationships

Ozempic and Wegovy are household names in a way that very few pharmaceutical brands achieve. I think the physician relationships Novo has built over more than 100 years of diabetes care create genuine stickiness, particularly with endocrinologists and primary care physicians who manage type 2 diabetes patients long-term. That brand trust does not evaporate quickly, even if a competing product shows slightly superior weight loss in a clinical trial.

4. Oral Semaglutide as a Differentiator

I find the oral semaglutide opportunity underappreciated in the current narrative. Rybelsus is already on the market, and Novo has been developing a higher-dose oral semaglutide pill for obesity specifically. If oral dosing becomes the preferred delivery mechanism for a meaningful share of patients (which I think it will over a 3-to-5-year horizon), Novo's head start in oral GLP-1 formulation is a real competitive advantage. Lilly does not currently have a commercialized oral GLP-1 product.

5. Pipeline Breadth: Amycretin and Beyond

Even with the CagriSema setback, I think the pipeline is not empty. Amycretin, a combined GLP-1/amylin receptor agonist, has shown early weight loss data that I find encouraging, with roughly 22% body weight reduction at 36 weeks in Phase I. This is pre-commercial and years away from approval, but it represents the next potential catalyst for Novo beyond CagriSema. I am watching the Phase II readout carefully.

Revenue Growth & Profitability

Earnings Per Share

Balance Sheet

I think the balance sheet is manageable but no longer pristine. Net debt of $15.1B against EBITDA of $22.2B (net debt / EBITDA of 0.68x) leaves adequate room to service obligations, and I am not concerned about near-term financial stress. The elevated debt reflects years of aggressive manufacturing investment and the buyback program. What I am watching is whether the 2026 revenue decline forces Novo to reduce its buyback activity or slow its CapEx cycle, either of which would be incrementally negative for my outlook.

3-Year Forecast

I am modeling three scenarios that bracket the range of outcomes I find plausible over a three-year horizon. The key variable in all three is the trajectory of GLP-1 market share and whether CagriSema receives FDA approval. I weight the base case most heavily at roughly 50%, bear at 25%, and bull at 25%, which implies a probability-weighted value of approximately $47, consistent with my HOLD rating.

Valuation

I use a blended approach to arrive at my $52 base price target, combining a discounted cash flow model with a forward P/E multiple analysis. My DCF uses a terminal growth rate of 2.5% and an equity risk premium of 5.5%, yielding a WACC of approximately 8.0% (risk-free rate 4.3%, beta 0.60). The pure DCF output is approximately $36.50 per share, which is actually below the current price and reflects the severity of the near-term earnings reset. I do not rely solely on the DCF, however, because I think the market will re-rate Novo on a forward P/E basis as earnings recover, and applying 14-15x to my FY2027 EPS estimate of $3.40 yields a price in the $48-51 range. My blended target is $52.

Sensitivity Analysis

I stress-tested my DCF across a range of WACC assumptions from 6.5% to 10.5% and terminal growth rates from 1.5% to 3.5%. I find the most plausible range for WACC is 7.5% to 9.0%, reflecting Novo's defensive pharma characteristics offset by the elevated pipeline uncertainty. My base case sits at WACC 8.0% and TGR 2.5%, highlighted below. The wide dispersion in outputs reinforces why I am at HOLD rather than a more directional rating.

Key Risks

1. CagriSema Competitive Positioning Risk

I think this is the most important risk I am tracking right now. The REDEFINE 4 trial showed that CagriSema produces meaningfully less weight loss than tirzepatide over 84 weeks (23% versus 25.5%). What concerns me most is that this was an open-label trial, which typically introduces bias favoring the unknown drug, and Novo still could not demonstrate non-inferiority. An FDA decision is expected in late 2026, and I believe there is a real probability that the label, if approved, comes with restrictions that limit its commercial appeal. Analysts at Jefferies have estimated that CagriSema could represent 15-25% of Novo's revenue by 2030 in a success scenario; a failure or limited label would eliminate that upside entirely.

2. Accelerating Market Share Loss to Eli Lilly

I am watching the US GLP-1 market share trend very carefully. In Q3 2025, Novo held 43% versus Lilly's 57%, down from approximately 80% international share as recently as 2024. The velocity of this shift concerns me. Lilly guided for approximately 25% revenue growth in 2026 while Novo guided for a decline, which tells me the prescription volume is continuing to shift. I do not think Novo will lose its semaglutide franchise, but the steady-state market share could settle well below 50%, which has material implications for my revenue forecasts.

3. US Drug Pricing Reform

I think the Most Favoured Nation executive order and the Medicaid obesity coverage rollback represent the most significant structural headwind in my model. The $4.2B 340B rebate reversal alone accounts for a meaningful portion of the 2026 guidance cut. I am monitoring whether these policy changes are reversed, modified, or expanded under the current administration. Any expansion of MFN pricing to additional drugs would be incrementally negative for my base case.

4. Compounding Pharmacy Competition

Even with FDA enforcement actions beginning in January 2026, I believe the compounding pharmacy channel will remain a competitive nuisance for Novo through at least mid-2026. Patients who were receiving cheaper compounded semaglutide from platforms like Hims and Hers are not guaranteed to immediately switch to Wegovy. I think this dynamic is weighing on volume in ways that are difficult to quantify precisely, and I would view a definitive FDA ban on compounded semaglutide, with effective enforcement, as a positive catalyst I am not fully modeling.

5. Gross Margin Compression

I am genuinely surprised by how quickly the gross margin has deteriorated, from 85.0% in FY2024 to 82.4% in FY2025. I expect further compression to approximately 79-81% in FY2026, driven by pricing reform, increased manufacturing costs from capacity expansion, and a less favorable product mix. If gross margins decline below 78%, I would need to revisit my base case price target downward.

6. Currency Risk (DKK / USD)

I want to flag this for US investors specifically. Novo Nordisk reports in Danish Krone (DKK), and the NVO ADR is priced in USD. A strengthening dollar versus the DKK translates directly into lower USD-equivalent earnings and revenue, even if the underlying DKK results are unchanged. I have converted all historical financials in this report at approximately 6.89 DKK per USD, which represents a reasonable average for recent periods, but this rate is not guaranteed to persist.

Final Verdict

Holder's Advisory: What Should You Do If You Already Own NVO?

This section is written specifically for investors who held NVO going into the two major shock events of early 2026. The guidance cut on February 3 and the CagriSema trial failure on February 24 were distinct events, and how you should think about your position today depends heavily on where you entered and how large the position is relative to your portfolio.

If You Entered Above $70 (Including the $80-$93 Range)

I think the most important thing to acknowledge if you are in this situation is that the fundamental narrative has genuinely changed, not temporarily paused. The CagriSema trial failure is not noise; it was a Phase III head-to-head trial that Novo had positioned as the clinical anchor for its next-generation obesity franchise, and it did not meet its endpoint. Combined with the 2026 revenue guidance reset, you are holding a company where the growth story that justified the 25-35x P/E it commanded at peak has materially weakened. That said, I would not recommend panic-selling at $38 if you have a multi-year horizon. The franchise is not broken. At 15x forward earnings with a 3.2% dividend yield, you are being compensated to wait. I would ask yourself two questions: Is this position sized appropriately for an investment that carries meaningful binary risk (CagriSema FDA decision, market share trajectory)? And do I have the conviction to hold through a possible further decline toward $30 if the bear case begins to unfold? If the answer to either question makes you uncomfortable, trimming to a position size you can hold without constant anxiety is a legitimate decision.

If You Entered Below $50 (Post-Selloff Entry)

I think your situation is more comfortable, but I would not become complacent. The 34% upside to my $52 base target is real, but so is the 35% downside to my $25 bear case. You are holding a balanced risk/reward, not a slam-dunk buy. My recommendation at this entry level is to hold your current position and set clear catalyst-based review points rather than a rigid price target. If Novo's Q1 2026 earnings (expected May 2026) show market share stabilizing or the CagriSema FDA submission process moving forward constructively, I would consider that a signal to build conviction. If market share continues to slide in Q1 and the FDA review timeline slips, I would treat that as a signal to reduce.

Key Catalysts I Am Watching Before Adding More

I am not willing to upgrade NVO to a BUY until I see at least one of the following materialize. First, a quarter of US GLP-1 market share stabilization, where NVO holds at or above 40% rather than continuing to decline. Second, a constructive FDA update on the CagriSema review, including a PDUFA date that signals the agency is engaged with the submission. Third, early commercial uptake data on the oral semaglutide pill for obesity, which I think is a genuinely underappreciated optionality that the market is currently not pricing. Fourth, clarity that the 2026 revenue guidance represents a trough and not the beginning of a multi-year structural decline. I will update this report when any of these catalysts arrive.

On Tax-Loss Harvesting for Those with Embedded Losses

If you are sitting on a significant unrealized loss in NVO (which many holders entering above $70 are), I think the current environment warrants at least a conversation about tax-loss harvesting. The 30-day wash sale rule prohibits repurchasing an identical security within 30 days of the sale, but you could sell NVO, capture the tax loss, and replace it temporarily with a broad healthcare ETF like XLV or a different pharma name before rotating back. This is not a recommendation to exit the position permanently; it is a mechanical observation that the embedded losses available to harvest are substantial, and the tax benefit is real. Consult your tax advisor before acting, as individual circumstances vary significantly.

The Bottom Line on Position Management

I rate NVO as a HOLD, not a SELL, because I believe the long-term GLP-1 market opportunity is intact, the franchise still generates approximately $22 billion in EBITDA annually, and the valuation is the most attractive it has been in five years. But I want to be honest: this is a show-me story right now, and the catalyst timeline extends into late 2026 and 2027. If you are holding NVO, I would size it to reflect that reality, watch the catalysts I have described, and resist the temptation to either panic sell or add aggressively before the fundamental picture begins to clarify.